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Tumor development requires facilitative alterations in the stroma. In this issue of Cancer Cell, Nguyen et al.
provide evidence that irradiation of mammary stroma drives accelerated development of mammary tumors
that are more likely to be estrogen receptor-negative and implicate stromal production of transforming
growth factor-b in this process.Many epidemiological studies have re-
vealed an increased risk of subsequent
cancer development in individuals ex-
posed to ionizing radiation (IR). As radia-
tion is well known to cause DNA damage
both directly and indirectly through induc-
tion of reactive oxygen species (ROS),
most investigations of IR as a carcinogen
have focused on how incorrect or ineffi-
cient repair of IR-induced DNA damage
could potentially lead to cancer-associ-
ated mutations. However, even strongly
activating oncogenic mutations are not
sufficient for tumor formationwithout facil-
itative changes in themicroenvironment of
the tumorcells (Bissell andRadisky, 2001),
changes, which can be caused by IR (Bar-
cellos-Hoff, 2010). Persistent alterations
induced by IR in the stroma surrounding
the developing cancer are known as
‘‘bystander’’ or ‘‘nontargeted effects,’’
and it is clear that these can be induced
by levels of radiation far below those
necessary to induce widespread DNA
damage (Barcellos-Hoff et al., 2005;
Wright, 2010).
Epidemiological studies have found that
women exposed to IR during mammary
gland development have an increased
risk of early onset cancers that are more
likely to be estrogen receptor-negative
(Castiglioni et al., 2007). The study re-
portedbyNguyenetal. (2011) in thecurrent
issueofCancerCellusesanelegant exper-
imental model to show how both of these
characteristics could be caused by the
effects of IR on the stroma, independent
of any direct effect of IR on the epithelium
(Figure 1). Differentiating the contribution
of stromal and epithelial tissue in the devel-
opment of mammary gland tumors can
be performed by transplanting mammary
gland tissue into cleared mammary fatpadsof isogenicmice. Transplanted tissue
deficient for expression of the tumor
suppressor Trp53 will eventually develop
tumorswithmanycharacteristicsofhuman
breast cancer, including heterogeneous
histology and differential expression of
estrogen receptor. Nguyen et al. (2011)
show that irradiation of mice prior to
implantation leads to significantly shorter
tumor latency, and this effect can be
observed even following exposure to low
levels of IR; doses as low as 10 centigrays
(cGy) are found to decrease tumor latency.
Nguyen et al. (2011) further show that this
effect is dependent upon stromal pro-
duction of transforming growth factor-b
(TGFb), as irradiation of Tgfb+/ mice prior
to transplantation did not significantly de-
crease tumor latency. Strikingly, a greater
proportion of the tumors that devel-
oped in the irradiated mice were found to
be deficient for expression of estrogen
receptor-a, although this effect appeared
to be independent of TGFb, as irradiation
increased the proportion of ERa-negative
tumors similarly in wild-type and Tgfb+/
mice.
How does stromal irradiation stimulate
thedevelopmentofnonirradiatedepithelial
tissue? Identification of the mechanism(s)
could potentially lead to interventions that
benefit individuals exposed to radiation,
reducing subsequent cancer incidence or
severity. Nguyen et al. (2011) implicate
stromal production of TGFb is as a compo-
nent of IR-induced tumor development.
Previous studies from the Barcellos-Hoff
group identified an IR-induced, ROS-
dependent mechanism by which latent
TGFb is converted into active TGFb in irra-
diated mammary glands (Barcellos-Hoff
et al., 1994), finding substantial andpersis-
tent activation even inmice given radiationCancer Celdoses as low as 10 cGy (Ehrhart et al.,
1997). IR-induced activation of TGFb can
induce fibrosis-like conditions, including
collagen deposition, which can disrupt
tissue structure and facilitate tumor inva-
sion (Radisky et al., 2007). Anothermecha-
nism bywhich irradiated stromamay stim-
ulate tumordevelopment is througheffects
on immune cells, which are known to play
critical roles in breast cancer develop-
ment. This could also occur through
TGFb, which is known to inhibit an endog-
enous anticancer gene program in cyto-
toxic T cells (Thomas and Massague,
2005). Alternatively, irradiation of C57Bl/6
mice was shown to stimulate an increase
in activated M2 macrophages (Coates
et al., 2008), immune cells that have been
linked to increased tumorigenesis in ex-
perimentalmodels and that are associated
with a poor prognosis in breast cancer
patients.
The study reported by Nguyen et al.
(2011) strikingly illustrates the significance
of both global environmental exposures
and consequent microenvironmental influ-
ences in determining whether susceptible
premalignant epithelial cells escape laten-
cy and go on to become malignant. At the
same time, this study brings into focus
many more unanswered questions, not
only with regard to the molecular mecha-
nisms alluded to above, but also relating
to the risks associated with human radia-
tion exposures. The lowest dose used in
this study, 10 cGy, is comparable to typical
mission doses on the International Space
Station (Barcellos-Hoff et al., 2005) and is
in the range of many medical procedures.
In light of the finding that even relatively
low doses of stromal irradiation can signif-
icantly affect later cancer development
from mutant epithelial cells, it will bel 19, May 17, 2011 ª2011 Elsevier Inc. 571
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Figure 1. Experimental Model to Define Radiation-Induced Stromal Effects on Tumor Development
In 3 week old mice, the rudimentary mammary epithelium can be completely removed through a surgical procedure known as fat pad clearance. Subsequent
allografting of mammary gland tissue into the cleared fat pads can lead to mammary ductal outgrowths and, if the transplanted epithelium is from a Trp53-defi-
cient mouse (Trp53/), eventual tumor development. When epithelium-cleared mice were irradiated with a dose of 10–100 cGy prior to allograft, tumors devel-
oped more quickly, and an increased proportion of the tumors were estrogen receptor-negative (ER). The radiation-induced reduction in tumor latency was
dependent upon stromal activation of TGFb, as tumor outgrowths from irradiated Tgfb+/ mice did not develop significantly faster than in nonirradiated mice.
By contrast, irradiation increased the proportion of ER tumors in mice of both genotypes, suggesting that this propensity may be independent of TGFb.
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Previewsimportant to better define the relationship
between thresholds of radiation exposure
and later cancer risk. It also is important
to better understand how the temporal
juxtaposition of radiation exposure and
mammary gland development contribute
to subsequent cancer risk. A thorough
understanding of these risk factors and
a more complete understanding of the
molecular mechanisms by which radiation
promotes later breast carcinogenesis is
necessary to better define effective inter-
ventions toprevent or reduce the incidence
of radiation-associated breast cancer.572 Cancer Cell 19, May 17, 2011 ª2011 ElsREFERENCES
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